BCAX vs NDSN · $1.51B cap vs P/E 31, rev $817.7M
Bicara Therapeutics Inc. Common Stock (BCAX) versus Nordson Corporation (NDSN) — a side-by-side from cached financials, not a winner call.
Bicara Therapeutics Inc. Common Stock (BCAX) is a biotechnology company listed on NASDAQ.
Nordson Corporation (NDSN) is a specialty industrial machinery company listed on NASDAQ.
BCAX does not have a complete income-statement cache yet.
Latest reported NDSN revenue for 2026-07-31 was $817.7M. Net income was $152.8M. Revenue was down 42.0% from 2026-04-30 to 2026-07-31. NDSN currently screens at market cap $16.17B and trailing P/E 31.0.
BCAX currently screens at market cap $1.51B. NDSN currently screens at market cap $16.17B and trailing P/E 31.0.
Not investment advice. Open the BCAX and NDSN stock pages for the full models.
Not investment advice.